【摘要】 分析探讨卡铂联合紫杉醇化疗联合手术治疗晚期卵巢癌的临床疗效。选择近5年于医我院接受治疗的90例晚期卵巢癌患者作为研究对象，按照接受治疗方式的不同进行分组。其中，实验组为接受卡铂和紫杉醇联合化疗并进行手术治疗的患者(n=45),对照组为仅接受手术切除并进行术后常规化疗的患者(n=45)。统计分析不同治疗方案下两组患者总生存率和无进展生存率的差异，使用RECIST标准对肿瘤的缓解情况进行评估，记录不同治疗方案下患者的疗效。采用EORTC的QLQ-C30量表对两组患者生活质量进行评估，比较两组患者治疗期间不良反应的发生情况。实验组患者1年、2年、3年总生存率及无进展生存率均明显高于对照组，两组患者上述结果比较差异均具有统计学意义(P<0.05)。实验组患者肿瘤完全缓解及部分缓解比例高于对照组患者，疾病进展比例低于对照组患者，实验组患者肿瘤缓解情况优于对照组，两组患者结果比较差异具有统计学意义(P<0.05)。实验组患者机体功能、情感功能、社会功能及全身健康状况评分均显著高于对照组，疼痛评分显著低于对照组，实验组患者生活质量优于对照组，两组患者结果比较差异具有统计学意义(P<0.05)。入组患者治疗期间不良反应主要表现为白细胞减少、恶心呕吐、神经系统毒性、脱发及消化道不适等，经对症处理后患者均已耐受，实验组出现上述不良反应29例，不良反应发生率为64.44%,对照组出现上述不良反应25例，不良反应发生率为55.56%,两组患者不良反应发生率的比较无明显统计学差异，不具有统计学意义(P>0.05)。卡铂联合紫杉醇化疗联合手术治疗晚期卵巢癌在提高总生存率和无进展生存率方面具有潜在优势。然而，需谨慎权衡其疗效与不良反应之间的平衡，同时充分考虑患者生活质量及安全性。更多还原

【Abstract】 To analyze and explore the clinical efficacy of combined carboplatin and paclitaxel chemotherapy alongside surgical intervention for the treatment of late-stage ovarian cancer, 90 patients diagnosed with late-stage ovarian cancer and treated at the institution over the past five years were selected for this study.Patients were categorized into two groups based on the treatment modality they received.The experimental group comprised patients(n=45) undergoing carboplatin and paclitaxel combination chemotherapy followed by surgical intervention, while the control group included patients(n=45) undergoing surgical resection followed by postoperative conventional chemotherapy.Statistical analysis was conducted to assess the differences in overall survival rate and progression-free survival rate between the two treatment regimens.Tumor response was evaluated using RECIST criteria to document the efficacy of each treatment approach.The EORTC QLQ-C30 scale was utilized to evaluate the quality of life in both patient groups, and occurrences of adverse reactions during the treatment period were compared.Patients in the experimental group exhibited significantly higher one-year, two-year, and three-year overall survival rates and progression-free survival rates compared to those in the control group, with statistically significant differences observed(P<0.05).The proportion of patients achieving complete or partial tumor remission in the experimental group was higher, while disease progression was lower compared to the control group.Statistical significance was noted in the comparison of tumor response between the two groups(P<0.05).The experimental group demonstrated significantly higher scores in physical functioning, emotional functioning, social functioning, and overall health status compared to the control group.Pain scores were notably lower in the experimental group, indicating a better quality of life.The occurrence of adverse reactions during the treatment period, including leukopenia, nausea/vomiting, neurotoxicity, alopecia, and gastrointestinal discomfort, was manageable in both groups without significant statistical difference in the incidence rate(P>0.05).Combined carboplatin and paclitaxel chemotherapy alongside surgical intervention for advanced-stage ovarian cancer presents potential advantages in improving overall survival and progression-free survival rates.However, careful consideration is necessary to balance its efficacy and adverse reactions, while also prioritizing patient quality of life and safety.更多还原